Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07048496 · ClinicalTrials.gov registry record · NA

Intravesical Treatment of Bladder Cancer at Home, Multi-modal Treatment Support

A NA study of Bladder Cancer, sponsored by University of Pennsylvania.

Recruiting
Registry status
NA
Development phase
50
Enrollment target
1
Study location

NCT07048496 is a NA study of Bladder Cancer that is actively recruiting participants, run by University of Pennsylvania. The registered enrollment target is 50 participants, below the 12,753-participant average among 175 other Bladder Cancer trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07048496, a NA study of Bladder Cancer, is actively recruiting participants, sponsored by University of Pennsylvania.

RECRUITING
Registry status
NA
Development phase
50 participants
Enrollment target
1
Study location

Study Summary

The proposed project will have two separate cohorts. The first will be to perform a more in-depth qualitative assessment of the barriers and facilitators for treatment compliance for non-muscle invasive bladder cancer. The second arm will be to create and test a BCG at home program. Participants in the second cohort will be enrolled in a conversational agent to measure patient symptoms and quality of life and improve self-efficacy.

Conditions Studied

Interventions

  • OTHER BCG delivery at home

Study Locations (1)

Pennsylvania

  • Abramson Cancer Center - Philadelphia

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2025-07-05
Est. Completion 2026-09-05
Phase NA

Sponsor

University of Pennsylvania

1,423 total trials

What the Registry Record Tells You About NCT07048496

The ClinicalTrials.gov registry entry for NCT07048496 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 12,753-participant average among 175 other Bladder Cancer trials with a reported enrollment target (100% lower). The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Bladder Cancer appearing as the primary indexed condition, and to 1 intervention - of which BCG delivery at home is the first listed.

NCT07048496 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT07048496 about?

NCT07048496 is a clinical study titled "Intravesical Treatment of Bladder Cancer at Home, Multi-modal Treatment Support". The proposed project will have two separate cohorts. The first will be to perform a more in-depth qualitative assessment of the barriers and facilitators for treatment compliance for non-muscle invasive bladder cancer. The second arm will be to create and test a BCG at home program. Participants in ...

What is the current status of trial NCT07048496?

This trial is currently recruiting. It is a NA study. The enrollment target is 50 participants. The study started on 2025-07-05. Estimated completion is 2026-09-05.

What conditions does trial NCT07048496 study?

This clinical trial studies the following conditions: Bladder Cancer.

What interventions are being tested in trial NCT07048496?

The interventions under investigation include: BCG delivery at home (OTHER).

Who is sponsoring clinical trial NCT07048496?

This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07048496 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Bladder Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.